Dr. Kenneth R. Meehan, MD

Dr. Meehan practices at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health.

Dr. Meehan's NPI, 1659469377, was assigned on October 10, 2006. Dr. Meehan graduated from Georgetown University School of Medicine in 1986. Dr. Meehan holds New Hampshire license 8825.

Dr. Meehan's primary practice is Dartmouth Hitchcock Medical Center, at 1 Medical Center Drive, Lebanon, NH 03756 in Grafton County. The practice phone is (603) 650-5000.

Dr. Meehan's primary practice is Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health. The medical group on file is Dartmouth Hitchcock Medical Center. Dmand AI also links Dr. Meehan to 1 more medical group, named with a free account. Dr. Meehan's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meehan practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Meehan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Meehan is licensed in New Hampshire.

CMS data shows 317 Medicare services from Dr. Meehan across 4 procedure codes in 2024, for 122 Medicare patients. Medicare paid $30,296 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 122 Medicare patients who saw Dr. Meehan in 2024. The largest group is 65 to 74, with 55 patients. 59% of them have high blood pressure, and 57% have high cholesterol. Their average risk score is 2.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Meehan's median patient age at 70, with 42% women.

In 2024, Dr. Meehan wrote 61 Medicare Part D claims for 24 patients. 61% of them were for generic drugs. CMS names the drug for 40 of them, across 3 drugs with 11 or more claims each, at $215,324 in total drug cost. In 2022, CMS named 39 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Meehan for performance year 2024, reported through an alternative payment model (APM). Dr. Meehan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Meehan as offering telehealth.

Dmand AI links 43 papers to Dr. Meehan, published from 2002 to 2024. 2020 was the busiest year, with 5. The most frequent topics are Hematopoietic Stem Cell Transplantation, Multiple Myeloma and Transplantation, Autologous. Dr. Meehan has published most often in Phys Rev Lett. Dr. Meehan's most frequent co-authors are John Mitchell Hill, MD, Parameswaran N. Hari, MD and Anita D'Souza, MD.

Dmand AI links Dr. Meehan to 3 clinical trials. Conditions studied include Hematologic Neoplasms, Waldenstrom Macroglobulinemia and Hematologic Diseases. Dartmouth-Hitchcock Medical Center sponsors the most, 2.

CMS Open Payments shows 43 general payments to Dr. Meehan from 7 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Celgene Corporation paid the most, $21,799.

Dr. Meehan graduated from Georgetown University School of Medicine in 1986.